Eli Lilly shares fall as competitor Novo notches coverage win for obesity drug Lilly reported first-quarter earnings that met analysts’ expectations, but investors were hoping for more

https://www.statnews.com/2025/05/01/eli-lilly-zepbound-mounjaro-novo-nordisk-cvs-caremark-obesity-weight-loss/?utm_campaign=breaking_news&utm_medium=email&_hsenc=p2ANqtz-9fC2DcfLB39A8Gp24IbLfBzJ2aqzFvRG7RCdeDSeZf-AxfDknp8AAjuHG0FclTs5YQd1is2LwHHn6n3tTtr8RIL-a6EQ&_hsmi=361803897&utm_content=361803897&utm_source=hs_email